Semaglutide for Alcohol Use Disorder
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05520775 |
Recruitment Status :
Completed
First Posted : August 30, 2022
Last Update Posted : May 8, 2024
|
Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill
Tracking Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | August 26, 2022 | ||||||||||||||||||
First Posted Date ICMJE | August 30, 2022 | ||||||||||||||||||
Last Update Posted Date | May 8, 2024 | ||||||||||||||||||
Actual Study Start Date ICMJE | September 2, 2022 | ||||||||||||||||||
Actual Primary Completion Date | April 12, 2024 (Final data collection date for primary outcome measure) | ||||||||||||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||||||||||||
Original Primary Outcome Measures ICMJE |
|
||||||||||||||||||
Change History | |||||||||||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||||||||||
Original Secondary Outcome Measures ICMJE |
|
||||||||||||||||||
Current Other Pre-specified Outcome Measures |
|
||||||||||||||||||
Original Other Pre-specified Outcome Measures |
|
||||||||||||||||||
Descriptive Information | |||||||||||||||||||
Brief Title ICMJE | Semaglutide for Alcohol Use Disorder | ||||||||||||||||||
Official Title ICMJE | Human Laboratory Screening of Semaglutide for Alcohol Use Disorder | ||||||||||||||||||
Brief Summary | This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder (AUD). | ||||||||||||||||||
Detailed Description | This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on laboratory alcohol responses and consumption, naturalistic alcohol consumption, and weight loss in participants with alcohol use disorder (AUD). Participants will attend weekly visits while semaglutide dosage is increased to 1.0mg over a period of approximately 9-10 weeks. Participants will attend weekly visits for medication or placebo administration. At scheduled intervals, participants will complete 4 laboratory sessions involving alcohol self-administration and alcohol challenge to characterize medication effects on alcohol-related outcomes. | ||||||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||||||
Study Phase ICMJE | Phase 2 | ||||||||||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Randomized parallel group design. Masking: Triple (Participant, Investigator, Outcomes Assessor)Primary Purpose: Basic Science |
||||||||||||||||||
Condition ICMJE |
|
||||||||||||||||||
Intervention ICMJE |
|
||||||||||||||||||
Study Arms ICMJE |
|
||||||||||||||||||
Publications * | Not Provided | ||||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||||
Recruitment Information | |||||||||||||||||||
Recruitment Status ICMJE | Completed | ||||||||||||||||||
Actual Enrollment ICMJE |
48 | ||||||||||||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||||||||||||
Actual Study Completion Date ICMJE | April 19, 2024 | ||||||||||||||||||
Actual Primary Completion Date | April 12, 2024 (Final data collection date for primary outcome measure) | ||||||||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||||||
Sex/Gender ICMJE |
|
||||||||||||||||||
Ages ICMJE | 21 Years to 65 Years (Adult, Older Adult) | ||||||||||||||||||
Accepts Healthy Volunteers ICMJE | Yes | ||||||||||||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||||||
Listed Location Countries ICMJE | United States | ||||||||||||||||||
Removed Location Countries | |||||||||||||||||||
Administrative Information | |||||||||||||||||||
NCT Number ICMJE | NCT05520775 | ||||||||||||||||||
Other Study ID Numbers ICMJE | 21-1689 R21AA026931-02 ( U.S. NIH Grant/Contract ) |
||||||||||||||||||
Has Data Monitoring Committee | Yes | ||||||||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||||||||||
Current Responsible Party | University of North Carolina, Chapel Hill | ||||||||||||||||||
Original Responsible Party | Christian Hendershot, MS, PhD, University of North Carolina, Chapel Hill, Research Associate Professor | ||||||||||||||||||
Current Study Sponsor ICMJE | University of North Carolina, Chapel Hill | ||||||||||||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||||||||||||
Collaborators ICMJE | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | ||||||||||||||||||
Investigators ICMJE |
|
||||||||||||||||||
PRS Account | University of North Carolina, Chapel Hill | ||||||||||||||||||
Verification Date | May 2024 | ||||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |